You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 163 No. 8, August 2009 TABLE OF CONTENTS
  Archives
  •  Online Features
  Article
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Topic Collections
 •Neonatology and Infant Care
 •Pediatrics, Other
 •Randomized Controlled Trial
 •Drug Therapy
 •Adverse Effects
 •Gastroenterology
 •Gastrointestinal Diseases
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

A Randomized Clinical Trial Measuring the Influence of Kefir on Antibiotic-Associated Diarrhea

The Measuring the Influence of Kefir (MILK) Study

Daniel J. Merenstein, MD; Jennifer Foster, BA; Frank D’Amico, PhD

Arch Pediatr Adolesc Med. 2009;163(8):750-754.

Objective  To examine the role of commercially available kefir, a fermented milk similar to yogurt but containing different fermentation microbes, in preventing antibiotic-associated diarrhea (AAD). Probiotics have shown some promise in preventing AAD.

Design  A double-blinded randomized placebo-controlled allocation concealment clinical trial.

Setting  Primary care patients in the Washington, DC, metropolitan area.

Participants  A total of 125 children aged 1 to 5 years presenting to primary care physicians.

Intervention  Kefir drink or heat-killed matching placebo.

Main Outcome Measure  The primary outcome was the incidence of diarrhea during the 14-day follow-up period in children receiving antibiotics.

Results  There were no differences in the rates of diarrhea per group, with 18% in the active group and 21.9% in the placebo group (relative risk, 0.82; 95% confidence interval, 0.54-1.43). Additionally, there were no differences in any secondary outcomes among the groups. However, there were some interesting interactions among initial health at enrollment, age of participants, and sex that require further study.

Conclusions  In our trial, kefir did not prevent AAD. Further independent research on the potential of kefir needs to be conducted.

Trial Registration  clinicaltrials.gov Identifier: NCT00481507


Author Affiliations: Department of Family Medicine, Georgetown University Medical Center, Washington, DC (Dr Merenstein and Ms Foster); University of Pittsburgh Medical Center, St Margaret's Hospital, Pittsburgh, Pennsylvania (Dr D’Amico).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2009 American Medical Association. All Rights Reserved.